Join
Live feed
·
INSIDERFilingvia Quantisnow
Jade Biosciences Inc. logo

Chief Executive Officer Frohlich Tom was granted 78,750 shares, increasing direct ownership by 1,039% to 86,331 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
JBIO· Jade Biosciences Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JBIO (Jade Biosciences Inc.) and more on Quantisnow.